Patrick Campbell

Novartis has announced the wet age-related macular degeneration treatment brolucizumab, which was backed by data from the HAWK and HARRIER trials, has received FDA approval.

A new study which reviewed data on more than 3 million patients found dog ownership was associated with a 24% reduced risk of all-cause mortality and a 65% reduced risk of mortality after a heart attack.

A recent study of primary practices in England found Asian patients were 15% less likely to be prescribed insulin, while black patients were half as likely to be prescribed a GLP-1 agonist or SGLT2 inhibitor.

George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.

A new study of children in West Virginia found associations birth weight and blood pressure as well as cholesterol and triglycerides at age 11.

The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.

A new study from the Harvard T.H. Chan School of Public Health found increasing consumption of sugary beverages, including 100% fruit juices, by half a serving per day could increase a person's risk of diabetes by 16%.

A recent study from the ACC Middle East Conference 2019 found patients with hypertension and type 2 diabetes who consume a high fiber diet had improvement in their blood pressure, cholesterol and fasting glucose.

A new study from the Ohio State University found the commonly-prescribed blood cancer drug ibrutinib was linked to new or worsening hypertension, which investigators suggest could contribute to an increase in other cardiovascular events.

A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.

A study from investigators in Europe found the CCS, ACC/AHA, and NICE guidelines for statin use may be more effective at preventing ASCVD events than ESC/EAS or USPSTF guidelines.

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.

A recent study of pregnancies from the Quebec Pregnancy Cohort found use of antidepressants during pregnancy was linked to an increased rate of gestational diabetes mellitus in an analysis that included more than 200,000 women from 1998 to 2015.

Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.

Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.

A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.

A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.

A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.

Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.

Gail Rodich, MD, discusses what the approval of rituximab, which has approvals for 9 other conditions including rheumatoid arthritis, means for pediatric patients with GPA and MPA.

Sheetal Desai, MD, a rheumatologist and investigator of the ongoing AWARE trial, discusses her clinical takeaways from the 52-week results and the importance of real-world evidence.

AWARE Trial investigator Aaron Broadwell, MD, discusses what new data was presented during CCR West and how it differed from a previously presented interim analysis.

Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.

A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.

Maria Greenwald, MD, rheumatologist with Desert Medical Advances, discusses the results of a study she conducted that sought to identify the most effective ways a physician can advise a patient on how to save money on treatments.

While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.

Discussing the importance of implementing a multidisciplinary team when treating conditions that put patients at a predisposition for comorbidities with Rania Al Asmar, MBBS, of Marshall University.

Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.

Elena Myasoedova, MD, of the Mayo Clinic, discusses the results of a study examining the incidence rates of cardiovascular disease in patients with rheumatoid arthritis across 3 decades.

Rania Al Asmar, MBBS, discusses a study she led and authored that examined prevalence and characteristics of patients with rheumatoid arthritis who later developed coronary artery disease.